StocksMedium•4 November 2026•
1 min read
BioCryst Q3 Earnings Beat Estimates Driven by Orladeyo Sales Growth
Key Facts
1BioCryst Pharmaceuticals delivered Q3 2026 results that exceeded expectations.
2The company maintained its 2026 financial guidance while highlighting the ongoing growth of Orladeyo.
3Management targets revenues exceeding $1 billion by 2030 through its current and pipeline drug portfolio.
BioCryst Pharmaceuticals delivered Q3 2026 results that exceeded analyst expectations. Seeking Alpha reported that the company maintained its full-year 2026 financial guidance as sales for its drug Orladeyo continued to grow. Management targets revenues exceeding $1 billion by 2030 through its current and pipeline drug portfolio.
BCRX closed at $8.57 on November 3, 2026, with the stock trading between a low of $8.19 and a high of $8.62 during that session. The earnings beat was supported by the market performance of Orladeyo in the hereditary angioedema (HAE) market, while investors remain focused on upcoming pipeline catalysts scheduled for 2027.